Molecular Biology of Human Ovarian Cancer

International Surgery

Volumn 81, Issue 2, 1996, Pages 152-157

  Chow, Song Nan ^a,b,d   Chien, Chin Hsiang ^c   Chen, Chin Tin ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Growth factor; Oncogene; Ovarian neoplasms; Tumor marker; Tumor suppressor genes

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLONY STIMULATING FACTOR 1; GROWTH FACTOR; IMMUNOSUPPRESSIVE ACID PROTEIN; LACTATE DEHYDROGENASE; PROTEIN P53; SIALIC ACID; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ARTICLE; GENE EXPRESSION; HUMAN; MOLECULAR BIOLOGY; ONCOGENE; ONCOGENE C ERB; ONCOGENE C MYC; ONCOGENE RAS; OVARY CANCER; TUMOR SUPPRESSOR GENE;

CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTRADIOL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENES, MYC; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES; OVARIAN NEOPLASMS; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 0029906157     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Woodruff JD, Julian CG. Multiple malignancy in the upper genital canal. Am J Obstet Gynecol 1969;103:810-822.
2. Jacobs IJ, Kohler MF, Wiseman RW et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity; p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992;84:1793-1798.
3. Mok CH, Tsao SW, Knapp RC, Fishbaugh PM, Lau CC. Unifocal origin of advanced human epithelial ovarian cancers: Cancer Res 1992;52:5119-5122.
4. Anzano MA, Roberts AB, Smith JM, Sporn MB, De Larco JE. Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proc Natl Acad Sci USA 1983;80:6264-6268.
5. Derynck R. Transforming growth factor-alpha: Structure and biological activities. J Cell Biochem 1986;32:203-204.
6. Derynck R. Transforming growth factor. Cell 1988;54:593-595.
7. Todaro GJ, Marquardt H, Twardzik DR, Reynolds FH jr, Stephenson JR. Transforming growth factors produced by viraltransformed and human tumor cells. In: Genes and Proteins in Oncogenesis. Vogel H, Weinstein IB, editors. New York:Raven Press, 1983:165-182.
8. Lee DC, Rochford RM, Todaro GS, Villareal LP. Developmental expression of rat transforming growth factor mRNA. Mol Cell Biol 1985;5:3644-3646.
9. Samsoondar J, Kobrin MS, Kudlow JE. Alpha-transforming growth factor secreted by untransformed bovine anterior pituitary cells in culture. I. Purification from conditioned media. J Biol Chem 1986;261:14408-14418.
10. Coffey RJ, Derynck R, Wilcox JN et al. Production and auto-induction of transforming growth factor in keratinocytes. Nature 1987;328:817-820.
11. Massague J. Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells. J Biol Chem 1983; 258:13614-13620.
12. Reynolds FH Jr, Todaro GJ, Fryling C, Stephenson JR. Human transforming growth factors induce tyrosine phosphorylation of EGF receptors. Nature 1983;292: 259-262.
13. Pike LJ, Marquardt H, Todaro GJ et al. Transforming growth factor and epidermal growth factor stimulate the phosphorylation of a synthetic, tyrosine-containing peptide in a similar manner. J Biol Chem 1982;257:14628-14631.
14. Sherwin SA, Twardzik DR, Bohn WH, Cockley KD, Todaro GJ. High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. Cancer Res 1983;43: 403-407.
15. Arteaga CL, Hanauske AR, Clark GM et al. Immunoreactive transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. Cancer Res 1988;48:5023-5028.
16. Bauknecht T, Kiechle M, Bauer G, Siebers JW. Characterization of growth factors in human ovarian carcinomas. Cancer Res 1986;46:2614-2618.
17. Chow SN. 1995, unpublished data.
18. Jindal SK, Snoey DM, Lobb DK, Dorrington JH. Transforming growth factor-α localization and role in surface epithelium of normal human ovaries and in ovarian carcinoma cells. Gynecol Oncol 1994;53:17-23.
19. Berchuck A, Rodriguez G, Olt G et al. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β. Am J Obstet Gynecol 1992;166: 676-684.
20. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncog 1993;4:493-540;
21. Varmus HE. Form and function of retroviral proviruses. Science 1982;216:812-820.
22. Bishop JM. Cellular oncogenes and retroviruses. Ann Rev Biochem 1983;52:301-354.
23. Hamlyn PH, Rabbitts TH. Translocation joins c-myc and immunoglobulin gamma-1 genes in a Burkitt lymphoma revealing a third exon in the c-myc oncogene. Nature 1983;304:135-139.
24. Notario V, Sukuma S, Santos E, Barbacid M. A common mechanism for the malignant activation of ras oncogenes in human neoplasia and in chemical induced animal tumours. In: Wonde Vande GF, Levine AJ, Topp WC, Watson JD, editors. Cancer Cell 2: Oncogenes and Viral Genes. Harbour, NY: Cold Spring Laboratory, 1984:425-432.
25. Bos JL, Toksoz D, Marshall CJ, et al. Amino acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukemia. Nature (Lond)1985;315:726-730.
26. McGrath J, Capon D, Goeddel D, Levinson A. Comparatives biochemical properties of normal and activated human ras p21 protein. Nature 1984;310:644-655.
27. Feig LA, Bast RC Jr, Knapp RC, Cooper GM. Somatic activation of K-ras gene in a human ovarian carcinoma. Science 1984;223: 698-701.
28. Filmus J, Trent JM, Pullano R, Buick RN. A cell line from a human ovarian carcinoma with amplification of the K-ras gene. Cancer Res 1986;46:5179-5182.
29. Van't Veer LJ; Hermens R, Van den Berg-Bakker LA et al. Ras oncogene activation in human ovarian carcinoma. Oncogene 1988;2:157-165.
30. Zhou DJ, Gonzalez-Cadavid N, Ahuja H et al. A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomas. cancer 1988;62:1573-1576.
31. Boltz EM, Kefford RF, Leary JA, Houghton CR, Friedlander ML. Amplification of c-ras Ki oncogene in human ovarian tumors. Int J Cancer 1989;43:428-430.
32. Fukumoto M, Estensen RD, Sha L et al, Association of Ki-ras with amplified DNA sequences, detected in human ovarian carcinomas by a modified in-gel renaturation assay. Cancer Res 1989;49:1693-1697.
33. Chien CH, Chang KT, Chow SN. Amplification and expression of c-Ki-ras oncogene in human ovarian cancer. Proc Natl Sci Counc B ROC 1990;14:27-32.
34. Chien CH, Chow SN. Point mutation of the ras oncogene in human ovarian cancer. DNA Cell Biol 1993;12:623-627.
35. Cole MD. The myc-oncogenes: its role in transformation and differentiation: Ann Rev Genet 1986;20: 361-384.
36. Serova OM. Amplification of c-myc proto-oncogene in primary tumours, metastasis and blood leukocytes of patients with ovarian cancer. Eksp Onkol 1987;9:25-27.
37. Baker VV, Borst MP, Dixon D et al. C-myc amplification in ovarian cancer. Gynecol Oncol 1990;38:340-342.
38. Sherr CJ, Rettenmier CW, Sacca R et al. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 1985;41:665-676.
39. Xu FJ, Ramakrishnan S, Daly L et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 1991;165:1356-1362.
40. Kacinski BM, Carter D, Kohorn EI et al. Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors. Yale J Biol Med 1989;62:379-392.
41. Kacinski BM, Carter D, Mittal K et al. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol 1990;137:135-147.
42. Wu S, Rodabaugh K, Martinez-Maza O et al. Stimulation of ovarian tumour cell proliferation with monocyte products including interleukin-1-alpha, interleukin-6 and tumour necrosis factor-alpha. Am J Obstet Gynecol 1992;166:997-1007.
43. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related proteins. Nature 1986;319:226-230.
44. Slamon DJ, Godolphin W, Jones LA et al. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
45. Berchuck A, Kamel A, Whitaker R et al. Over expression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091.
46. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP. Human p53 gene localized to short arm of chromosome 17. Nature 1986;319:783-784.
47. Levine AJ, Momand J. Tumor suppressor gene: the p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta 1990;1032:119-136.
48. Steinmeyer K, Deppert W. DNA binding properties of murine p53. Oncogene 1988;3:501-507.
49. Marks JR, Davidoff AM, Kerns BJ et al. Over expression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51:2979-2984.
50. Eccles D, Cranston G, Gruber L et al. Allele losses in human epithelial ovarian carcinoma (EOC) and immunohistochemical detection of mutant p53 protein. Proc Am Soc Clin Oncol 1991; 10:A198.
51. Okamoto A, Sameshima Y, Yokoyama S et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991;51:5171-5176.
52. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer: a late event? Oncogene 1991;6:1685-1690.
53. Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983;35:603-610.
54. Dang CV, Lee WMF. Identification of the human c-myc protein nuclear translocation signal. Mol Cell Biol 1988;8:4048-4049.
55. Eilers M, Schirm S, Bishop JM. The myc protein activates transcription of the a-prothymosin gene. EMBO J 1991;10:133-141.
56. Chien CH, Wang FF, Hamilton TC. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mole Cell Endocrinol 1994;99:11-19.
57. Pietenpol JA, Stein RW, Moran E et al. TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 1990;61:777-785.
58. Murphy LJ, Bell GI, Friesen HG. Growth hormone stimulates sequential induction of c-myc and insulin-like growth factor I expression in vivo. Endocrinol 1987;120:1806-1812.
59. Dubik D, Denbinski TC, Shiu RPC. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation. Cancer Res 1987;47:6517-6521.
60. Renpel SA, Johnston RN. Steroid-induced cell proliferation in vivo is associated with increased c-myc proto oncogene transcript abundance. Development 1988; 104:87-95.
61. Chow SN, Chen YP. Primary ovarian cancer. Int Surg 1987;72: 154-159.
62. Chen CK, Chow SN, Chen RJ et al Primary ovarian cancer at National Taiwan University Hospital: 1980-1989. Int Surg 1994; 79:48-51.
63. Braunstein GD, Thompson R, Princier GL, Mclntire KR. Trophoblastic proteins as tumour markers in noseminomatous germ cell tumors. Cancer 1986;57:1842-1845.
64. Bast RC Jr, Klug TL, ST John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887.
65. Altaras MM, Goldberg GL, Levin W et al. The value of cancer antigen-125 as a tumour marker in malignant germ cell tumors of the ovary. Gynecol Oncol 1986;25:150-159.
66. Kivinen S, Kuoppala T, Leppilampi M, Vuori J, Kauppila A. Tumour associated antigen CA 125 before and during the treatment of ovarian carcinoma. Obstet Gynecol 1986;67:468-472.
67. Panza N, Pacilio G, Campanella L et al Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin antigen as serum markers of epithelial ovarian carcinoma. Cancer 1988;61:76-83.
68. Pastner B, Mann WJ, Vissicchio M, Leosch M. Comparison of serum CA 125 and lipid-associated sialic acid (LASA-P) in monitoring patients with invasive, ovarian adenocarcinoma. Gynecol Oncol 1988;30:98-103.
69. Jacobs I, Bast RC jr. The CA 125 tumor-associated antigen: a review of the literature. Human Reprod 1989;4:1-12.
70. Einhorn N, Sjovall K, Knapp RC et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol;1992;80:14-18.
71. Bast RC Jr, Klug TL, Schaetzl E et al Monitoring human ovarian carcinoma with a combination of Ca 125, Ca 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol 1984; 149:553-559.
72. Hay DL, Murphy JR. Evaluating human chorionic gonadotropin heterogeneity in nongestational malignancy with monoclonal immunoassays. Oncology 1987;44:174-179.
73. Sawada M, Okudaira Y, Matsui Y. Immunosuppressive acidic protein in patients with ovarian cancer. Cancer 1983;52:2081-2085.
74. Castelli M, Romano P, Atlante G. Immunosuppressive acidic protein (IAP) and Ca 125 assays in detection of human ovarian cancer: preliminary results. Int J Biol Markers 1987;2:187-190.
75. Lin YH, Chow SN, Chen CK et al. Evaluation of immunosuppressive acidic protein in human ovarian cancer. J Formos Med Assoc 1994;93:776-780.
76. Sheiko MC, Hart WR. Ovarian germinoma (dysgerminoma) with elevated serum lactic dehydrogenase: case report and review of literatures. Cancer 1982;49:994-998.
77. Awais GM. Dysgerminoma and serum lactic dehydrogenase levels. Obstet Gynecol 1983;61:99-101.
78. Chow SN, Chien CH, Chang FM, Hsieh CY, Ouyang PC. Serum total lactic dehydrogenase levels and its isoenzymes in ovarian cancer. J Obstet Gynecol ROC 1987;26:233-244.
79. Chow SN, Wu CC, Huang SC, Tsai YL, Chien CH. Combined analysis of serum lactic dehydrogenase levels and isoenzyme patterns in ovarian neoplasms. Proc Natl Sci Counc B ROC 1991; 15:101-104.
80. Schwartz PE, Chambers SK, Chambers JT et al. Circulating tumour markers in the monitoring of gynecologic malignancies. Cancer 1987;60:353-361.
81. Vardi JR, Tadros GH, Foemmel R, Shebes M. Plasma lipid-associated aialic acid and serum Ca 125 as indicators of disease status with advanced ovarian cancer. Obstet Gynecol 1989;74:379-383.
82. Chow SN, Chien CH, Chen YP et al. Serum levels of total sialic acid and lipid-associated sialic acid in ovarian cancer. J Obstet Gynecol ROC 1995;34:1-6.
83. Zurawski VR Jr, Knapp RC, Einhorn N et al. An initial,analysis, of preoperative serum CA 125 levels in patients with early stage ovarian carcinomas. Gynecol Oncol 1988;30:7-14.
84. Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. Cancer Detect Prev 1988;12:321-355.
85. Mackay EV, Khoo SK, Daunter B. Tumour markers. In:Coppleson M, Monaghan J, Morrow CP, Tatter MH, editors. Gynecologic Oncology. 2nd edition. Edinburgh, London, Melbourne, New York and Tokyo: Churchill Livingstone, 1992:405-415.